ArticleCancer immunology, immunotherapy : CII2019

Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.

Yuexin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.